The Future of Drug Development: the Economics of Pharmacogenomics

John A. Vernon (jvernon@business.uconn.edu) and W. Keener Hughen (keener.hughen@business.uconn.edu)

Working Papers from eSocialSciences

Abstract: This paper models how the evolving field of pharmacogenomics (PG), which is the science of using genomic markers to predict drug response, may impact drug development times, attrition rates, costs,and the future returns to research and development (R&D). While there still remains an abundance of uncertainty around how PG will impact the future landscape of pharmaceutical and biological R&D, we identify several likely outcomes. We conclude PG has the potential to significantly reduce both expected drug development costs (via higher probabilities of technical success, shorter clinical development times, and smaller clinical trials) and returns. The impact PG has on expected returns is partially mitigated by higher equilibrium prices, expedited product launches, and longer effective patent lives. The conclusions are, of course, accompanied by numerous caveats. [NBER Working Paper no. 11875]

Keywords: drug development; pharmacogenomics; clinical development; drug response; genomic markers; attrition rates; research and development; clinical trials; Economics; Heatlh Studies (search for similar items in EconPapers)
Date: 2006-08
Note: Institutional Papers
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://www.esocialsciences.org/Download/repecDownl ... s&AId=589&fref=repec

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ess:wpaper:id:589

Access Statistics for this paper

More papers in Working Papers from eSocialSciences
Bibliographic data for series maintained by Padma Prakash (padmaprakash@esocialsciences.com).